Watson Pharmaceuticals Incorporated (WPI) Upgraded by RBC Capital (RY

Watson Pharmaceuticals Incorporated (NYSE: WPI) was upgraded by investment analysts at RBC Capital (NYSE: RY) from a “sector perform” rating to an “outperform” rating in a note issued to investors on Wednesday.Separately, analysts at Bank of America (NYSE: BAC) upgraded shares of Watson Pharmaceuticals Incorporated to a “buy” rating in a research note to investors on Wednesday. Analysts at Collins Stewart cut their price target on shares of Watson Pharmaceuticals Incorporated from $75.00 to $60.00 in a research note to investors on Wednesday. They now have a “neutral” rating on the stock. Also, analysts at Morgan Stanley (NYSE: MS) upgraded shares of Watson Pharmaceuticals Incorporated from an “equal weight” rating to an “overweight” rating in a research note to investors on Wednesday. They now have a $65.00 price target on the stock.Watson Pharmaceuticals, Inc. (Watson) is an integrated global pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic and brand pharmaceutical products. It operates in three segments: Global Generics, Global Brands and Distribution. It operates in international markets, including Western Europe, Canada, Australasia, Asia, South America and South Africa with its commercial market being the United States of America. As of December 31, 2010, it marketed approximately 160 generic pharmaceutical product families and approximately 30 brand pharmaceutical product families in the United States, and distributed approximately 8,500 stock-keeping units (SKUs) through its Distribution Division. In January 2010, the Company acquired 64% of Eden Biopharm Group Limited (Eden). In May 2011, it acquired Specifar Pharmaceuticals S.A.Watson Pharmaceuticals Incorporated traded up 2.79% on Wednesday, hitting $57.45. Watson Pharmaceuticals Incorporated has a 52-week low of $53.46 and a 52-week high of $73.35. The stock has a 50-day moving average of $60.82 and a 200-day moving average of $65.24. The company has a market cap of $7.305 billion and a price-to-earnings ratio of 38.44.